RESUMO
INTRODUCTION: At a single-center pediatric hospital, the neurokinin-1 receptor antagonist aprepitant was used to treat refractory pruritus in epidermolysis bullosa (EB) and atopic dermatitis (AD). METHODS: Thirty-seven patients were included (24 EB patients, 13 AD patients), ages 10 months to 37 years. RESULTS: 58% (14/24) of patients with EB and 85% (11/13) of patients with AD reported aprepitant was effective in decreasing their pruritus, with age-related differences in efficacy observed in EB patients, and access to the medication by insurance denial or availability of the drug as a barrier to use. CONCLUSIONS: Aprepitant shows promise in controlling refractory pruritus in pediatric EB and AD patients and deserves further study.
Assuntos
Aprepitanto , Dermatite Atópica , Epidermólise Bolhosa , Prurido , Humanos , Aprepitanto/uso terapêutico , Prurido/tratamento farmacológico , Prurido/etiologia , Criança , Estudos Retrospectivos , Masculino , Feminino , Adolescente , Pré-Escolar , Lactente , Dermatite Atópica/complicações , Dermatite Atópica/tratamento farmacológico , Adulto , Adulto Jovem , Epidermólise Bolhosa/complicações , Epidermólise Bolhosa/tratamento farmacológico , Resultado do Tratamento , Antagonistas dos Receptores de Neurocinina-1/uso terapêuticoRESUMO
ABSTRACT: This position paper summarizes the current understanding of the medical management of chronic pancreatitis (CP) in children in light of the existing medical literature, incorporating recent advances in understanding of nutrition, pain, lifestyle considerations, and sequelae of CP. This article complements and is intended to integrate with parallel position papers on endoscopic and surgical aspects of CP in children. Concepts and controversies related to pancreatic enzyme replacement therapy (PERT), the use of antioxidants and other CP medical therapies are also reviewed. Highlights include inclusion of tools for medical decision-making for PERT, CP-related diabetes, and multimodal pain management (including an analgesia ladder). Gaps in our understanding of CP in children and avenues for further investigations are also reviewed.